非小细胞肺癌患者外周血AEG-1mRNA的表达及临床意义

The expression of AEG-1 mRNA in peripheral blood of patients with non-small cell lung cancer and its clinical significance

目的:探讨非小细胞肺癌患者外周血AEG-1 mRNA的表达情况及其临床意义。方法:收集104例新诊断的非小细胞肺癌患者外周血标本,RT-PCR法检测AEG-1 mRNA表达水平,分析其与临床病理特征之间的关系。对其中52例接受含铂方案化疗的晚期患者随访12个月,探讨外周血AEG-1 mRNA表达水平与化疗反应率及无进展生存期之间的关系。结果:非小细胞肺癌患者外周血高表达AEG-1 mRNA,其表达水平与肿瘤分期(P=0.015)、组织分化程度(P=0.048)和远处转移(P=0.007)密切相关。接受含铂方案一线化疗的52例晚期患者中,AEG-1 mRNA高表达者较低表达者对含铂方案化疗反应率低(25.0%vs58.3%,P=0.015),中位无进展生存期短(5.25 vs 8.25个月,P=0.019)。结论:非小细胞肺癌外周血AEG-1mRNA高表达提示肿瘤分期晚、组织分化差、转移率高。外周血AEG-1 mRNA表达有可能成为晚期非小细胞肺癌患者含铂方案一线化疗的疗效预测和预后因子。

Objective ： To detect the expression of AEG - 1 mRNA in peripheral blood of patients with non - small cell lung cancer and to investigate its clinical significance. Methods：AEG - 1 mRNA was detected in the peripheral blood of 104 patients with newly diagnosed non -small cell lung cancer（NSCLC） by reverse transcription polymerase chain reaction. The relationship between AEG - 1 mRNA expression level and clinical characteristics of NSCLC pa- tients were analyzed. 52 patients with advanced disease were treated with platinum - based first - line chemothera- py and were followed up for 12 months. The relationship of AEG - 1 mRNA expression to chemotherapeutic effi- cacy and progression free survival was explored. Results：AEG - 1 mRNA was highly expressed in the peripheral blood of NSCLC patients. AEG - 1 mRNA expression was correlated with tumor stage （P = 0.015 ）, differentiation （ P = 0. 048 ）, and distant metastasis（ P = 0. 007 ）. Of the 52 advanced patients treated with platinum - based first - line chemotherapy, high AEG - 1 mRNA expression predicted a poor responsive rate （25.0% vs 58.3 % , P = 0.015 ） and a short progression free survival（5.25 vs 8.25 months,P =0. 019）. Conclusion：High AEG - 1 mRNA expres- sion in peripheral blood of NSCLC correlates with advanced stage, poor differentiation and high metastatic incidence. AEG- 1 mRNA expression in peripheral blood is likely to become a predictive and prognostic factor for advanced NSCLC patients who received platinum -based first -line chemotherapy.